RBM39 and Wilms tumor: This spliceosomal vulnerability likely extends to other components of the spliceosomal machinery such as HNRNPA1 [26], RBM39 [28] and SNRPD3 [47], as well as other cancers such as Wilms’ tumour, where our transcriptomic analyses revealed MYCN regulation of spliceosome regulators including SNRPD1 and WDR77 [48].